LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission of the Concave Supra-arch Branched Stent-Graft System into Special Examination and Approval Procedure for Innovative Medical Devices

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors ("**Directors**") of the Company is pleased to announce that on 9 January 2026, the Company obtained formal written notice from the National Medical Products Administration ("**NMPA**") confirming that the Concave Supra-arch Branched Stent-Graft System (the "**CS™ Stent-Graft System**" or the "**Product**"), a product jointly developed by Professor Shu Chang of Fuwai Hospital, the Chinese Academy of Medical Sciences of the National Centre for Cardiovascular Diseases, and the Group, has been admitted into the NMPA Special Examination and Approval Procedure for Innovative Medical Devices (the "**Procedure**"). The Product is suitable for the minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers. It represents the world's first integrated triple-branched reconstruction solution for aortic arch diseases aimed at eliminating cerebral ischemia and the 17th product of the Company having obtained admission to the Procedure.

The aortic arch lesion, with its complex anatomical structures and unique hemodynamics, is considered one of the most challenging fields on the "technical high ground" of vascular surgery and endovascular intervention. Through long-term clinical exploration, various branch reconstruction techniques have continued to evolve and mature. However, achieving the higher goal of complete endovascular integrated reconstruction of the three branches of the aortic arch has long been hindered by the lack of specialized devices truly adapted to the complex anatomy of

the arch and capable of synchronous reconstruction of all three branches of the aortic arch. In response to this challenge, Professor Shu Chang's team, in collaboration with the Company, has developed the CS™ Stent-Graft System through dedicated research and innovation. It is specifically designed for complete endovascular reconstruction of the three branches of the aortic arch and adopts a unique concave and integrated structure, which fundamentally addresses the multiple technical challenges faced by traditional endovascular techniques in achieving complete triple-branched reconstruction of the aortic arch, offering a truly systematic, minimally invasive, safer, and more effective solution for complex aortic arch lesion.

- Unique "concave design" conforms to the anatomical structure of the aortic arch, eliminating the risk of cerebral ischemia;

- The integrated structure ensures safety and reliability, preventing endoleaks and maintaining high branch patency rate;

- Rapid pacing assistance is unnecessary and precise deployment can be achieved solely through blood pressure control;

- Simplified positioning and alignment, easier branch selection and smoother surgical operation.

The feasibility study (First-in-Man study) of the CS™ Stent-Graft System, led by Professor Shu Chang as the principal investigator (PI), completed enrollment of all 10 patients in June 2023. The 12-month postoperative follow-up results demonstrated excellent apposition of the stent graft to the aortic arch and the arch branches, with no occurrence of endoleaks, patency of all branch arteries, and absence of adverse events, thus providing preliminary validation of the safety and efficacy of this innovative product.

Subsequently, the "prospective, multicenter, single-arm objective performance criteria" registration clinical trial was initiated. The trial plans to enroll 103 patients across 25 leading centers nationwide. As of 31 August 2025, 52 patients have been enrolled. The interim clinical results further validate the clinical value and application prospects of the CS™ Stent-Graft System with respect to complete endovascular triple-branched reconstruction of the aortic arch:

- Immediate technical success rate: 100%;

- 30-day postoperative all-cause mortality rate: only 1.92%;

- 30-day postoperative disabling stroke rate: only 1.92%;

- No occurrence of severe complications such as permanent paraplegia or retrograde type A aortic dissection;

- No occurrence of device-related adverse events.

The Group possesses independent intellectual property rights to the Product. Currently, the Product has been successfully implanted in multiple clinical cases in Germany, Switzerland, Greece, and Hong Kong, China. Its exceptional performance and clinical value have gained high recognition and widespread attention from international clinical experts. The Company anticipates that there will be richer evidence-based medicine (EBM) evidence to further confirm the safety and effectiveness of the Product.

The Board believes that the admission of the Product into the Procedure will shorten its registration process and accelerate its market launch. It is expected that the launch of the Product will benefit patients with aortic arch aneurysms and ulcers, while simultaneously expanding the product portfolio of the Company. This will contribute to building the world's most comprehensive minimally invasive aortic treatment solution, covering three critical technical areas, namely endovascular reconstruction of aortic arch branches, visceral branches, and internal iliac arteries, which will comprehensively advance the treatment of aortic diseases into a new stage of development characterized by greater safety, precision, and efficiency.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 12 January 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu and Ms. FENG Xiaoling being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. WANG Wansong, Mr. ZHOU Luming and Ms. CHEN Dongxia being independent non-executive Directors.